Three million people worldwide are taking the new, heavily advertised anti-cholesterol drugs Zetia and Vytorin, despite a lack of clinical evidence that they reduce cardiovascular disease or heart attacks, or help patients live longer. Vytorin and Zetia brought in $5.2 billion last year for Merck and Schering-Plough, placing them among the best-selling drugs in the world. The Food and Drug Administration approves many drugs based on whether they perform a specific action, like lowering cholesterol, without requiring long-term trials on whether they extend life or lower disease risks. Other FDA-approved drugs have been found to be ineffective or even dangerous.
Best-Selling Cholesterol Drugs Found Ineffective
Authorities in France have placed more than a third of the country under a red heat...
An influenza outbreak has reportedly sickened more than 150 recruits in training at Lackland air force...
One morning early last July, Micha Bitsinnie arrived at work to an onslaught of messages from...
